Literature DB >> 26910880

Cohort of Iranian Patients with Congenital Agammaglobulinemia: Mutation Analysis and Novel Gene Defects.

Hassan Abolhassani1,2, Massimiliano Vitali3, Vassilios Lougaris3, Silvia Giliani3, Nima Parvaneh1, Leila Parvaneh1, Babak Mirminachi1, Taher Cheraghi4, Hosseinali Khazaei5, Seyed Alireza Mahdaviani6, Fatemeh Kiaei1, Naiimeh Tavakolinia1, Javad Mohammadi7, Babak Negahdari8, Nima Rezaei1, Lennart Hammarstrom2, Alessandro Plebani3, Asghar Aghamohammadi1.   

Abstract

OBJECTIVES: Impairment in early B-cell development can cause a predominantly antibody deficiency with severe depletion of peripheral B-cells. Mutations in the gene encoding for Bruton's-tyrosine-kinase (BTK) and the components of the pre-B-cell receptor complex or downstream signaling molecules have been related to this defect in patients with agammaglobulinemia.
METHODS: Iranian patients with congenital agammaglobulinemia were included and the correlation between disease-causing mutations and parameters such as clinical and immunologic phenotypes were evaluated in available patients.
RESULTS: Out of 87 patients, a molecular investigation was performed on 51 patients leading to identification of 39 cases with BTK (1 novel mutation), 5 cases of µ-heavy chain (3 novel mutations) and 1 case of Igα-deficiencies.
CONCLUSION: Although there is no comprehensive correlation between type of responsible BTK mutation and severity of clinical phenotype, our data suggest that BTK-deficient and autosomal recessive agammaglobulinemia patients differ significantly regarding clinical/immunologic characteristics.

Entities:  

Keywords:  Autosomal recessive agammaglobulinemia; Bruton’s tyrosine kinase; Genotype-phenotype correlation; Long-term cohort; X-linked agammaglobulinemia

Mesh:

Substances:

Year:  2016        PMID: 26910880     DOI: 10.1586/1744666X.2016.1139451

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  4 in total

1.  Primary antibody deficiencies in Turkey: molecular and clinical aspects.

Authors:  Sinem Firtina; Yuk Yin Ng; Ozden H Ng; Ayca Kiykim; Esra Yucel Ozek; Manolya Kara; Elif Aydiner; Serdar Nepesov; Yildiz Camcioglu; Esra H Sayar; Ezgi Yalcin Gungoren; Ismail Reisli; Selda H Torun; Sule Haskologlu; Tuba Cogurlu; Aysenur Kaya; Sukru Cekic; Safa Baris; Ugur Ozbek; Ahmet Ozen; Muge Sayitoglu
Journal:  Immunol Res       Date:  2021-10-07       Impact factor: 2.829

2.  Targeted RNAseq Improves Clinical Diagnosis of Very Early-Onset Pediatric Immune Dysregulation.

Authors:  Kiera Berger; Dalia Arafat; Shanmuganathan Chandrakasan; Scott B Snapper; Greg Gibson
Journal:  J Pers Med       Date:  2022-06-01

3.  Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication.

Authors:  Asghar Aghamohammadi; Hassan Abolhassani; Necil Kutukculer; Steve G Wassilak; Mark A Pallansch; Samantha Kluglein; Jessica Quinn; Roland W Sutter; Xiaochuan Wang; Ozden Sanal; Tatiana Latysheva; Aydan Ikinciogullari; Ewa Bernatowska; Irina A Tuzankina; Beatriz T Costa-Carvalho; Jose Luis Franco; Raz Somech; Elif Karakoc-Aydiner; Surjit Singh; Liliana Bezrodnik; Francisco J Espinosa-Rosales; Anna Shcherbina; Yu-Lung Lau; Shigeaki Nonoyama; Fred Modell; Vicki Modell; Mohamed-Ridha Barbouche; Mark A McKinlay
Journal:  Front Immunol       Date:  2017-06-13       Impact factor: 7.561

4.  Fourth Update on the Iranian National Registry of Primary Immunodeficiencies: Integration of Molecular Diagnosis.

Authors:  Hassan Abolhassani; Fatemeh Kiaee; Marzieh Tavakol; Zahra Chavoshzadeh; Seyed Alireza Mahdaviani; Tooba Momen; Reza Yazdani; Gholamreza Azizi; Sima Habibi; Mohammad Gharagozlou; Masoud Movahedi; Amir Ali Hamidieh; Nasrin Behniafard; Mohammamd Nabavi; Mohammad Hassan Bemanian; Saba Arshi; Rasol Molatefi; Roya Sherkat; Afshin Shirkani; Reza Amin; Soheila Aleyasin; Reza Faridhosseini; Farahzad Jabbari-Azad; Iraj Mohammadzadeh; Javad Ghaffari; Alireza Shafiei; Arash Kalantari; Mahboubeh Mansouri; Mehrnaz Mesdaghi; Delara Babaie; Hamid Ahanchian; Maryam Khoshkhui; Habib Soheili; Mohammad Hossein Eslamian; Taher Cheraghi; Abbas Dabbaghzadeh; Mahmoud Tavassoli; Rasoul Nasiri Kalmarzi; Seyed Hamidreza Mortazavi; Sara Kashef; Hossein Esmaeilzadeh; Javad Tafaroji; Abbas Khalili; Fariborz Zandieh; Mahnaz Sadeghi-Shabestari; Sepideh Darougar; Fatemeh Behmanesh; Hedayat Akbari; Mohammadreza Zandkarimi; Farhad Abolnezhadian; Abbas Fayezi; Mojgan Moghtaderi; Akefeh Ahmadiafshar; Behzad Shakerian; Vahid Sajedi; Behrang Taghvaei; Mojgan Safari; Marzieh Heidarzadeh; Babak Ghalebaghi; Seyed Mohammad Fathi; Behzad Darabi; Saeed Bazregari; Nasrin Bazargan; Morteza Fallahpour; Alireza Khayatzadeh; Naser Javahertrash; Bahram Bashardoust; Mohammadali Zamani; Azam Mohsenzadeh; Sarehsadat Ebrahimi; Samin Sharafian; Ahmad Vosughimotlagh; Mitra Tafakoridelbari; Maziar Rahimi; Parisa Ashournia; Anahita Razaghian; Arezou Rezaei; Setareh Mamishi; Nima Parvaneh; Nima Rezaei; Lennart Hammarström; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2018-10-09       Impact factor: 8.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.